American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24)

In the placebo-controlled ORBITA-COSMIC* trial, an implantable coronary sinus reducer (CSR) does not increase transmural myocardial perfusion, but it reduces the frequency of angina and improves quality of life (QoL) in patients with no further antianginal options.

Use of transcatheter aortic valve implantation (TAVI) does not increase the risks and contributes to a decrease in the rates of death or stroke at 1 year in patients with severe aortic stenosis when compared with surgical aortic-valve replacement (SAVR), suggests a study presented at ACC.24.

Using intravascular ultrasound (IVUS) to guide stent placement in patients with acute coronary syndrome (ACS) appears to reduce the 1-year risk of target vessel failure as compared with using angiography alone, according to the results of the IVUS-ACS study.

Among patients with atherosclerotic cardiovascular disease (ASCVD) who fail to achieve guideline-directed low-density lipoprotein cholesterol (LDL-C) goals despite receiving maximally tolerated statins, initiating inclisiran immediately resulted in significant reductions in LDL-C, according to the VICTORION-INITIATE trial presented at ACC.24.

Self-selecting for nonprescription statin therapy with the help of a Web-based application leads to a high percentage of individuals correctly confirming their eligibility, using the medication appropriately, and achieving significant low-density lipoprotein cholesterol (LDL-C) reductions, according to the results of the TACTiC trial.

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

In the CRESCENT trial, a mandibular advancement device (MAD) was noninferior to a continuous positive airway pressure (CPAP) machine for reducing 24-hr mean arterial blood pressure (MBP) in individuals with obstructive sleep apnoea (OSA), uncontrolled hypertension, and high cardiovascular (CV) risk.